These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 23555741)

  • 1. Evaluation of in vitro cross-reactivity to avian H5N1 and pandemic H1N1 2009 influenza following prime boost regimens of seasonal influenza vaccination in healthy human subjects: a randomised trial.
    Bethell D; Saunders D; Jongkaewwattana A; Kramyu J; Thitithayanont A; Wiboon-ut S; Yongvanitchit K; Limsalakpetch A; Kum-Arb U; Uthaimongkol N; Garcia JM; Timmermans AE; Peiris M; Thomas S; Engering A; Jarman RG; Mongkolsirichaikul D; Mason C; Khemnu N; Tyner SD; Fukuda MM; Walsh DS; Pichyangkul S
    PLoS One; 2013; 8(3):e59674. PubMed ID: 23555741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine.
    Rudenko L; Naykhin A; Donina S; Korenkov D; Petukhova G; Isakova-Sivak I; Losev I; Stukova M; Erofeeva M; Nikiforova A; Power M; Flores J
    Hum Vaccin Immunother; 2015; 11(12):2839-48. PubMed ID: 26697973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial.
    Pitisuttithum P; Boonnak K; Chamnanchanunt S; Puthavathana P; Luvira V; Lerdsamran H; Kaewkungwal J; Lawpoolsri S; Thanachartwet V; Silachamroon U; Masamae W; Schuetz A; Wirachwong P; Thirapakpoomanunt S; Rudenko L; Sparrow E; Friede M; Kieny MP
    Lancet Infect Dis; 2017 Aug; 17(8):833-842. PubMed ID: 28533093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined administration of MF59-adjuvanted A/H5N1 prepandemic and seasonal influenza vaccines: long-term antibody persistence and robust booster responses 1 year after a one-dose priming schedule.
    Lopez P; Caicedo Y; Sierra A; Tilman S; Clemens R; Banzhoff A
    Clin Vaccine Immunol; 2013 May; 20(5):753-8. PubMed ID: 23536690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Analysis of Antibodies Induced by Vaccination with 4 Kinds of Avian Influenza H5N1 Pre-Pandemic Vaccines.
    Ohshima N; Iba Y; Kubota-Koketsu R; Yamasaki A; Majima K; Kurosawa G; Hirano D; Yoshida S; Sugiura M; Asano Y; Okuno Y; Kurosawa Y
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33050014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
    Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F
    Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
    Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
    J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A live attenuated H5N2 prime- inactivated H5N1 boost vaccination induces influenza virus hemagglutinin stalk specific antibody responses.
    Kongchanagul A; Samnuan K; Wirachwong P; Surichan S; Puthavathana P; Pitisuttithum P; Boonnak K
    Vaccine; 2020 Jan; 38(4):852-858. PubMed ID: 31708176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential Immunization With Live-Attenuated Chimeric Hemagglutinin-Based Vaccines Confers Heterosubtypic Immunity Against Influenza A Viruses in a Preclinical Ferret Model.
    Liu WC; Nachbagauer R; Stadlbauer D; Solórzano A; Berlanda-Scorza F; García-Sastre A; Palese P; Krammer F; Albrecht RA
    Front Immunol; 2019; 10():756. PubMed ID: 31105689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
    Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients.
    van der Velden MV; Geisberger A; Dvorak T; Portsmouth D; Fritz R; Crowe BA; Herr W; Distler E; Wagner EM; Zeitlinger M; Sauermann R; Stephan C; Ehrlich HJ; Barrett PN; Aichinger G
    Clin Vaccine Immunol; 2014 Jun; 21(6):867-76. PubMed ID: 24739978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell-mediated cross-strain protective immunity elicited by prime-boost vaccination with a live attenuated influenza vaccine.
    Li J; Arévalo MT; Chen Y; Chen S; Zeng M
    Int J Infect Dis; 2014 Oct; 27():37-43. PubMed ID: 25172265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection against H5N1 highly pathogenic avian and pandemic (H1N1) 2009 influenza virus infection in cynomolgus monkeys by an inactivated H5N1 whole particle vaccine.
    Nakayama M; Shichinohe S; Itoh Y; Ishigaki H; Kitano M; Arikata M; Pham VL; Ishida H; Kitagawa N; Okamatsu M; Sakoda Y; Ichikawa T; Tsuchiya H; Nakamura S; Le QM; Ito M; Kawaoka Y; Kida H; Ogasawara K
    PLoS One; 2013; 8(12):e82740. PubMed ID: 24376571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial.
    Nicholson KG; Abrams KR; Batham S; Clark TW; Hoschler K; Lim WS; Medina MJ; Nguyen-Van-Tam JS; Read RC; Warren FC; Zambon M
    Lancet Infect Dis; 2011 Feb; 11(2):91-101. PubMed ID: 21168369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterosubtypic protection against avian influenza virus by live attenuated and chimeric norovirus P-particle-M2e vaccines in chickens.
    Ghorbani A; Ngunjiri JM; Xia M; Elaish M; Jang H; Mahesh KC; Abundo MC; Jiang X; Lee CW
    Vaccine; 2019 Feb; 37(10):1356-1364. PubMed ID: 30691981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans.
    Crowe BA; Brühl P; Gerencer M; Schwendinger MG; Pilz A; Kistner O; Koelling-Schlebusch K; Aichinger G; Singer J; Zeitlinger M; Müller M; Ehrlich H; Barrett PN
    Vaccine; 2010 Dec; 29(2):166-73. PubMed ID: 21055500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of single, homologous prime-boost and heterologous prime-boost immunization strategies against H5N1 influenza virus in a mouse challenge model.
    Sabarth N; Howard MK; Savidis-Dacho H; van Maurik A; Barrett PN; Kistner O
    Vaccine; 2010 Jan; 28(3):650-6. PubMed ID: 19896446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seasonal influenza vaccine elicits heterosubtypic immunity against H5N1 that can be further boosted by H5N1 vaccination.
    van Maurik A; Sabarth N; Dacho HS; Brühl P; Schwendinger M; Crowe BA; Noel Barrett P; Kistner O; Keith Howard M
    Vaccine; 2010 Feb; 28(7):1778-85. PubMed ID: 20018265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults.
    Lazarus R; Kelly S; Snape MD; Vandermeulen C; Voysey M; Hoppenbrouwers K; Hens A; Van Damme P; Pepin S; Leroux-Roels I; Leroux-Roels G; Pollard AJ
    PLoS One; 2016; 11(11):e0165384. PubMed ID: 27814377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.